Quick Answer
SUPERNUS PHARMACEUTICALS, INC. reported R&D Expense of $106.23 million for fiscal year 2025.
SUPERNUS PHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $106.23M | -2.4% |
| 2024 | $108.80M | +18.8% |
| 2023 | $91.59M | +22.9% |
| 2022 | $74.55M | -17.6% |
| 2021 | $90.47M | +19.1% |
| 2020 | $75.96M | +9.9% |
| 2019 | $69.10M | -22.5% |
| 2018 | $89.21M | +79.9% |
| 2017 | $49.58M | +15.9% |
| 2016 | $42.79M | +46.9% |
| 2015 | $29.14M | +48.8% |
| 2014 | $19.59M | +13.6% |
| 2013 | $17.25M | -26.7% |
| 2012 | $23.52M | -23.2% |
| 2011 | $30.63M | -12.9% |
| 2010 | $35.15M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $29.37M | +1.1% | +32.8% |
| June 30, 2025 | $22.11M | -15.5% | -17.9% |
| March 31, 2025 | $26.93M | +8.0% | -7.3% |
| September 30, 2024 | $29.04M | +28.2% | +10.9% |
| June 30, 2024 | $26.18M | +7.4% | +5.0% |
| March 31, 2024 | $24.93M | +17.5% | +10.0% |
| September 30, 2023 | $22.66M | +15.9% | -7.1% |
| June 30, 2023 | $24.38M | +48.8% | +14.9% |
- SUPERNUS PHARMACEUTICALS, INC. showed a decrease of -2.4% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, SUPERNUS PHARMACEUTICALS, INC.’s r&d expense has grown by 202.2% (from $35.15 million to $106.23 million).
- The most recent figure is from SUPERNUS PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: